Since GABRB2 downregulation inhibits PI3K/AKT activation (28), DEHP-induced dysregulation of GABRB2 may synergize with T3 receptor mutations to amplify PI3K signaling, accelerating tumor development. Here, AKT1 is linked to neoplasm.